Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR positive, Wild type KRAS status confers therapeutic sensitivity to Cetuximab in patients with Colorectal Adenocarcinoma.
This statement is based on a regulatory approval from the Health Canada:
ERBITUX (cetuximab) is indicated as a single agent in patients who are intolerant to irinotecan-based chemotherapy for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC).